Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
Produced by Haymarket Medical Education
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and is a leading cause of stroke, heart failure, cardiovascular morbidity, and sudden death. Diagnosis can be challenging; many individuals with AF do not experience any symptoms and thus are not aware that they are at increased risk for cerebrovascular events. Screening of asymptomatic patients has been proposed as a way of identifying individuals likely to beneﬁt from prophylactic anticoagulation prior to the onset of arrhythmia symptoms, thus reducing the burden of stroke.
In this innovative roundtable activity, 4 clinical experts discuss the magnitude of undiagnosed nonvalvular atrial fibrillation (NVAF) and screening protocols for symptomatic individuals as well for as those with “silent” AF. Evidence-based anticoagulation strategies are reviewed in detail, as are considerations for selection of therapy. The importance of implementing a collaborative care model to improve patient health outcomes is discussed, as is the need to incorporate a comprehensive approach to shared decision-making.
This curriculum is designed for primary care physicians, allied healthcare professionals (eg, nurse practitioners and physician assistants), and cardiologists involved in the care of patients with cardiovascular disease.
After completing the activity, the participant should be better able to:
Describe the magnitude of undiagnosed NVAF, including risk factors and clinical and cost implications
Initiate suitable screening protocols for patients at risk of developing NVAF and for those who may have silent atrial fibrillation
Participate in individualized treatment planning and administration of care, guided by the most up-to-date management practices and informed by clinical evidence
Implement collaborative care models to improve patient care, including a comprehensive approach to shared decision-making
Conflict Of Interest Disclosure Policies
In accordance with the ACCME Standards for Commercial Support, Heart Rhythm Society (HRS) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HRS resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Furthermore, HRS seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HRS is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
Peter Salgo, MD—Moderator Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons Associate Director, Surgical Intensive Care Columbia University Medical Center New York, NY
Dr. Salgo has no relevant financial relationships to disclose.
James Daubert, MD Professor of Medicine Chief, Cardiac Electrophysiology Duke University Medical Center Durham, NC
Dr. Daubert has received honoraria and/or consulting fees from the American College of Cardiology (as Associate Editor for JACC-EP); ARCA Biopharma; Biotronik; Boston Scientific; Medtronic; St. Jude; VytronUS, Inc.; LivaNova PLC; and Zoll Medical Corporation. He has received research grants and/or fellowship funds from ARCA Biopharma; Biosense Webster, Inc.; Boston Scientific; Gilead Sciences, Inc.; Medtronic; NIH/NHLBI; and St. Jude and is on the advisory boards of Biosense Webster, Inc.; Gilead Sciences, Inc.; Iowa Approach, LLC; and Medtronic.
Paul Doghramji, MD, FAAFP Attending Physician Collegeville Family Practice Medical Director, Health Services Ursinus College Collegeville, PA
Dr. Doghramji has been on the advisory boards of and has received honoraria and/or consulting fees from Alkermes, Harmony Pharmaceuticals, and Jazz Pharmaceuticals and has stock and/or stock options in Pfizer Inc.
Kelly M. Rudd, PharmD, FCCP, BCPS, CACP Director, Network Pharmacy Operations Clinical Pharmacy Specialist, Anticoagulation Bassett Healthcare Network Cooperstown, NY
Dr. Rudd has no relevant financial relationships to disclose.
Charles Vega, MD, FAAFP Health Sciences Clinical Professor UC Irvine Department of Family Medicine Associate Dean for Diversity and Inclusion UC Irvine School of Medicine Irvine, CA
Dr. Vega has received honoraria and/or consulting fees from and is a speaker and/or consultant for Johnson & Johnson and Shire Pharmaceuticals.
HRS’ physician content reviewers have no relevant financial relationships to disclose.
Accredited Provider Disclosure
The staff of HRS and HME involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Heart Rhythm Society (HRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
HRS designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Participants should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
Faculty, speakers, presenters, authors, activity medical directors, and moderators are required to disclose to the learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved) as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Bristol-Myers Squibb and Pfizer Alliance. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.